Chronic hepatitis C is a viral infection (HCV) which can lead to serious liver disorders such as cirrhosis and liver cancer. Today HCV is one of the leading causes of liver failure requiring transplantation in the United States. Despite what is commonly written in the media, HCV is curable in many patients. Currently treatments involve antiviral medications (DAA's) for 8 to 12 weeks. The Section of Gastroenterology and Hepatology was involved in the cutting edge research leading to the FDA approval of currently used HCV therapies. The late world renowned hepatologist and gastroenterologist, Luis Balart, MD, MACG describes in the video below the HCV research that was taking place within the Section.
For more information please call 504-988-5344
